Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Apply
RAS(ON) Inhibitor
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step